TY - JOUR
T1 - Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999–2016
AU - Lee, Chun On
AU - Li, Hang Long
AU - Tsoi, Man Fung
AU - Cheung, Ching Lung
AU - Cheung, Bernard Man Yung
N1 - Funding Information:
This work was supported by an Undergraduate Research Internship from the Li Ka Shing Faculty of Medicine, University of Hong Kong, awarded to Chun-On Lee.
Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Background: The liver fat score (LFS) has been proposed to be a simple non-invasive marker of non-alcoholic fatty liver disease (NAFLD), which is highly prevalent in the general population. We tested its association with cardiovascular diseases (CVDs) and prognosis. Methods: 17,244 adult participants from the National Health and Nutrition Examination Survey 1999–2016 were included. LFS is calculated from variables including serum aspartate transaminase/alanine transaminase (AST/ALT) ratio, fasting serum aspartate transaminase (AST) level, fasting serum insulin level, presence of metabolic syndrome and diabetes mellitus. In cross-sectional analysis, logistic regression was used to examine the association of the LFS with coronary heart disease (CHD), myocardial infarction (MI), congestive heart failure (CHF), stroke and angina pectoris. Mortality during follow-up was analysed using Cox proportional hazard regression. Results: LFS was associated with CHD (adjusted odds ratio [OR]: 1.09 per standard deviation [SD], 95% confidence interval [95% CI]: 1.03–1.15) (p =.003), CHF (1.11, 1.04–1.18) (p =.003) and angina pectoris (1.08, 1.02–1.13) (p =.005). LFS was not associated with MI or stroke, but was associated with increased all-cause and cardiovascular mortality with hazard ratios (HRs) of 1.10 (95% CI: 1.07–1.13) (p <.001) and 1.12 (95% CI: 1.06–1.17) (p <.001), respectively. Conclusions: NAFLD is usually asymptomatic, but this large study of a large general population shows that LFS is associated with CHD, CHF, angina pectoris, cardiovascular and all-cause mortality. Determining the LFS is worthwhile, as it identifies people with NAFLD, who may also be at increased cardiovascular risk.Key Messages Liver fat score (LFS), a non-invasive marker of non-alcoholic fatty liver disease (NAFLD), is associated with coronary heart disease (CHD), congestive heart failure (CHF) and angina. LFS is also associated with increased cardiovascular and all-cause mortality. Determining the LFS is worthwhile as it identifies people with NAFLD as well as increased cardiovascular risk.
AB - Background: The liver fat score (LFS) has been proposed to be a simple non-invasive marker of non-alcoholic fatty liver disease (NAFLD), which is highly prevalent in the general population. We tested its association with cardiovascular diseases (CVDs) and prognosis. Methods: 17,244 adult participants from the National Health and Nutrition Examination Survey 1999–2016 were included. LFS is calculated from variables including serum aspartate transaminase/alanine transaminase (AST/ALT) ratio, fasting serum aspartate transaminase (AST) level, fasting serum insulin level, presence of metabolic syndrome and diabetes mellitus. In cross-sectional analysis, logistic regression was used to examine the association of the LFS with coronary heart disease (CHD), myocardial infarction (MI), congestive heart failure (CHF), stroke and angina pectoris. Mortality during follow-up was analysed using Cox proportional hazard regression. Results: LFS was associated with CHD (adjusted odds ratio [OR]: 1.09 per standard deviation [SD], 95% confidence interval [95% CI]: 1.03–1.15) (p =.003), CHF (1.11, 1.04–1.18) (p =.003) and angina pectoris (1.08, 1.02–1.13) (p =.005). LFS was not associated with MI or stroke, but was associated with increased all-cause and cardiovascular mortality with hazard ratios (HRs) of 1.10 (95% CI: 1.07–1.13) (p <.001) and 1.12 (95% CI: 1.06–1.17) (p <.001), respectively. Conclusions: NAFLD is usually asymptomatic, but this large study of a large general population shows that LFS is associated with CHD, CHF, angina pectoris, cardiovascular and all-cause mortality. Determining the LFS is worthwhile, as it identifies people with NAFLD, who may also be at increased cardiovascular risk.Key Messages Liver fat score (LFS), a non-invasive marker of non-alcoholic fatty liver disease (NAFLD), is associated with coronary heart disease (CHD), congestive heart failure (CHF) and angina. LFS is also associated with increased cardiovascular and all-cause mortality. Determining the LFS is worthwhile as it identifies people with NAFLD as well as increased cardiovascular risk.
KW - Cardiovascular disease prevention
KW - liver fat score
KW - metabolic syndrome
KW - non-alcoholic fatty liver disease score
UR - https://www.scopus.com/pages/publications/85109164627
U2 - 10.1080/07853890.2021.1943514
DO - 10.1080/07853890.2021.1943514
M3 - Article
C2 - 34184611
AN - SCOPUS:85109164627
SN - 0785-3890
VL - 53
SP - 1065
EP - 1073
JO - Annals of Medicine
JF - Annals of Medicine
IS - 1
ER -